Polymyositis and dermatomyositis secondary prevention: Difference between revisions
| Line 9: | Line 9: | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
*Effective measures for the secondary prevention of polymyositis and dermatomyositis include: | *Effective measures for the secondary prevention of polymyositis and dermatomyositis include: | ||
** Assessment for malignancy initially and annually for three years including: | ** Assessment for malignancy initially and annually for three years including:<ref name="TiniakouMammen2015">{{cite journal|last1=Tiniakou|first1=Eleni|last2=Mammen|first2=Andrew L.|title=Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review|journal=Clinical Reviews in Allergy & Immunology|volume=52|issue=1|year=2015|pages=20–33|issn=1080-0549|doi=10.1007/s12016-015-8511-x}}</ref> | ||
*** Chest CT scan | *** Chest CT scan | ||
*** Abdomen CT scan | *** Abdomen CT scan | ||
Revision as of 19:19, 11 April 2018
|
Polymyositis and dermatomyositis Microchapters |
|
Differentiating Polymyositis and dermatomyositis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Polymyositis and dermatomyositis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Polymyositis and dermatomyositis secondary prevention |
|
FDA on Polymyositis and dermatomyositis secondary prevention |
|
CDC on Polymyositis and dermatomyositis secondary prevention |
|
Polymyositis and dermatomyositis secondary prevention in the news |
|
Blogs on Polymyositis and dermatomyositis secondary prevention |
|
Risk calculators and risk factors for Polymyositis and dermatomyositis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].
Secondary Prevention
- Effective measures for the secondary prevention of polymyositis and dermatomyositis include:
- Assessment for malignancy initially and annually for three years including:[1]
- Chest CT scan
- Abdomen CT scan
- Pelvic CT scan
- Assessment for malignancy initially and annually for three years including:[1]
References
- ↑ Tiniakou, Eleni; Mammen, Andrew L. (2015). "Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review". Clinical Reviews in Allergy & Immunology. 52 (1): 20–33. doi:10.1007/s12016-015-8511-x. ISSN 1080-0549.